K. Eis

发表

Substituted imidazo [1,2b] pyridazines as kinase inhibitors, their production and use as pharmaceuticals

Judith Günther, U. Zügel, B. Bader, 2005 .

Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.

F. Prinz, D. Suelzle, B. Nicke, 2019, Journal of medicinal chemistry.

Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069

Lindsay C. Westlake, M. Meyerson, A. Cherniack, 2022, Journal of medicinal chemistry.

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

H. Briem, P. Lienau, P. Nussbaumer, 2017, ChemMedChem.

Photochemistry Meets Natural‐Product Synthesis

K. Eis, G. Quinkert, 2007 .

Abstract 2: Discovery of BAY 2402234 by phenotypic screening: A human Dihydroorotate Dehydrogenase (DHODH) inhibitor in clinical trials for the treatment of myeloid malignancies

Sven Christian, D. Scadden, A. Haegebarth, 2019, Cancer Chemistry.

Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction

H. Briem, G. Siemeister, D. Moosmayer, 2019, Proceedings of the National Academy of Sciences.

BAY 1143269, a novel MNK1 inhibitor, targets oncogenic protein expression and shows potent anti-tumor activity.

P. Lienau, D. Mumberg, C. Lange, 2017, Cancer letters.

Kinase Data Mining: Dealing with the Information (Over‐)Flow

K. Eis, G. Kettschau, R. Jautelat, 2005, Chembiochem : a European journal of chemical biology.

Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C

Clara D. Christ, P. Steigemann, H. Briem, 2020, ChemMedChem.

Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.

E. Nigg, G. Siemeister, F. Barr, 2007, Molecular biology of the cell.

BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.

H. Briem, P. Lienau, S. Hammer, 2021, Journal of medicinal chemistry.

Automated medicinal chemistry.

Knut Eis, Marcus Koppitz, M. Koppitz, 2006, Drug discovery today.

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

H. Briem, P. Lienau, U. Luecking, 2020, Journal of medicinal chemistry.

Identification of Small Molecules that Modulate Mutant p53 Condensation

A. Kamburov, P. Steigemann, M. Lange, 2020, iScience.

Novel YAP1/TAZ pathway inhibitors identified through phenotypic screening with potent anti-tumor activity via blockade of GGTase-I / Rho-GTPase signaling

B. Nicke, P. Lienau, L. Potze, 2023, bioRxiv.

Correction to “Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069”

Lindsay C. Westlake, M. Meyerson, A. Cherniack, 2022, Journal of medicinal chemistry.

Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.

P. Lienau, E. Pook, Jonathan T. Goldstein, 2022, Bioorganic & medicinal chemistry.

Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.

A. Schlicker, P. Lienau, L. Potze, 2024, Cell chemical biology.